ArticleInternal and emergency medicine2024
The gut-pancreas axis: investigating the relationship between microbiota metabolites and pancreatic steatosis.
Article in Internal and emergency medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of fatty pancreas and its associations with pancreatic disease and metabolic disorders: a systematic review and meta-analysis of 124 studies.Frontiers in nutrition · 2026Pooled it
- The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer.Medical oncology (Northwood, London, England) · 2026Review
- The Gut-Skin Axis in Atopic Dermatitis and Inflammatory Bowel Disease: Mechanisms, Microbiota, and Therapeutic Implications.Journal of personalized medicine · 2026Review
- Establishment and Comparative Analysis of Four Mouse Models for the Study of Pancreatic Steatosis.International journal of molecular sciences · 2026Article
- High serum uric acid as a marker for fatty pancreas disease in Chinese women with overweight/obesity.BMC endocrine disorders · 2025Article
- Retrospective study: analysis of risk factors and construction of prediction model for pancreatic steatosis.BMC gastroenterology · 2025Article
- Implications of gut microbiota in hepatic and pancreatic diseases: Gut-liver-pancreas axis.World journal of hepatology · 2025Article
- The causal dance: trimethylamine N-oxide, obesity, and acute pancreatitis in pathophysiological harmony.Human cell · 2025Article
- Association between intra-pancreatic fat deposition and diseases of the exocrine pancreas: A narrative review.World journal of gastroenterology · 2025Review
- Gut-to-tumor translocation of multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- The Clinical Significance of Pancreatic Steatosis in Pancreatic Cancer: A Hospital-Based Study.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of pancreatic steatosis has increased and it has been linked to the rising prevalence of metabolic syndrome. Metabolic syndrome is known to have a strong connection with changes in intestinal microbiota. The aim of this study was to explore the relationship between pancreatic steatosis and the levels of trimethylamine N-oxide (TMAO) and butyrate. In this study, 136 individuals were randomly selected from outpatient clinics at Firat University Hospital. The study evaluated their demographic characteristics, anthropometric measurements, and biochemical parameters. The presence of pancreatic steatosis was assessed using abdominal ultrasonography. Additionally, the levels of TMAO and butyrate were measured. The mean age of individuals in the study was 44.5 ± 14.6. 84 of the subjects were females. Using the waist circumference, 61 were considered obese and 34 overweight. The detection rate of pancreatic steatosis was found to be 70.6%. The study found that individuals with steatosis had higher average age, presence of hepatic steatosis, BMI, waist circumference measurements, and presence of metabolic syndrome than those without steatosis. A significantly higher butyrate level was detected in those without steatosis (p = 0.001). TMAO levels were slightly higher in patients without steatosis than in those with steatosis; however, this was insignificant. Pancreatic steatosis is highly associated with alterations in levels of microbiota metabolites, indicating a potential role of these metabolites in the pathogenesis of the disease and subsequent therapeutic targets. Several other factors, such as age, hepatic steatosis, diabetes, and waist circumference, have also been identified as potential predictors of pancreatic steatosis.
Indexed as
Identifiers
38981984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.